Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers | Globalization and Health BioMed Central Research Transparency in Nigeria s public pharmaceutical sector perceptions from policy makers Habibat A Garubaf Jillian C Kohler t and Anna M Huisman Open Access Address Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario Canada Email Habibat A Garuba - Jillian C Kohler - Anna M Huisman - Corresponding author tEqual contributors Published 29 October 2009 Received 30 March 2009 J . I m I inz HI. r I Accepted 29 October 2009 Globalization and Health 2009 5 14 doi l 744-8603-5-14 This article is available from http content 5 1 14 2009 Garuba et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract_ Background Pharmaceuticals are an integral component of health care systems worldwide thus regulatory weaknesses in governance of the pharmaceutical system negatively impact health outcomes especially in developing countries 1 . Nigeria is one of a number of countries whose pharmaceutical system has been impacted by corruption and has struggled to curtail the production and trafficking of substandard drugs. In 2001 the National Agency for Food and Drug Administration and Control NAFDAC underwent an organizational restructuring resulting in reforms to reduce counterfeit drugs and better regulate pharmaceuticals 2 . Despite these changes there is still room for improvement. This study assessed the perceived level of transparency and potential vulnerability to corruption that exists in four essential areas of Nigeria s pharmaceutical sector registration .
